IceCure - Model ICE3 - Trial – Cryoablation of Low Risk Breast Cancer

We are dedicated to providing reliable clinical support for the ProSense™ System, so that physicians and other stakeholders can adopt our technology with confidence as the gold standard in tumor therapy. ICE3 is the largest controlled multilocation clinical trial ever performed for liquid nitrogen (LN2) –based cryoablation of small, low-risk, early-stage malignant breast tumors without subsequently removing them. The trial began in 2014 and has completed recruitment of 206 patients in 19 hospitals and medical centers across the US, including Columbia University Medical Center and Mount Sinai Beth Israel.